Patents Issued in November 10, 2016
  • PRODUCTS AND PHARMACEUTICAL COMPOSITIONS
    Publication number: 20160324860
    Abstract: The present invention relates to a product comprising a PDE1 inhibitor and a PDE2 inhibitor, in free or salt form, pharmaceutical compositions comprising them and their use as pharmaceuticals for the treatment of cAMP and/or cGMP related disorders.
    Type: Application
    Filed: January 8, 2015
    Publication date: November 10, 2016
    Applicant: Intra-Cellular Therapies, Inc.
    Inventors: Joseph HENDRICK, Jennifer O'BRIEN, Gretchen SNYDER, Peng LI, Lawrence P. WENNOGLE
  • SUBSTITUTED PYRROLOPYRIMIDINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
    Publication number: 20160324861
    Abstract: Provided herein are Pyrrolopyrimidine Compounds having the following structure: wherein R1, R2, R3, and L are as defined herein, compositions comprising an effective amount of a Pyrrolopyrimidine Compound, and methods for treating or preventing breast cancer, more particularly triple negative breast cancer, comprising administering an effective amount of such Pyrrolopyrimidine Compounds to a subject in need thereof.
    Type: Application
    Filed: July 21, 2016
    Publication date: November 10, 2016
    Inventors: Andrew Antony Calabrese, Brandon Jeffy, Dale Robinson, Dan Zhu, Dehua Huang, Jan Elsner, John Boylan, Lida Tehrani, Mark A. Nagy, Raj Kumar Raheja, Paul Erdman, Rama K. Narla, Roy L. Harris, Tam Minh Tran, Jennifer Riggs, Yuhong Ning, Shuichan Xu
  • ADRENOCEPTORS ANTAGONISTS FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE CONDITIONS
    Publication number: 20160324862
    Abstract: The present invention teaches methods for treating a variety of neurodegenerative conditions, including Alzheimer's disease (AD) and idiopathic Parkinson's disease (iPD), by utilizing adrenoceptor antagonists. Adrenoceptor antagonists that can be used include ?-blockers, such as acebutolol, betaxolol, bisopropolol, bopindolol, carvedilol, metoprolol, oxprenolol, propranolol, and timolol.
    Type: Application
    Filed: June 27, 2014
    Publication date: November 10, 2016
    Inventors: Michele Tagliati, Gennaro Pagano
  • TARGETED CANCER TREATMENT BY HSP90 INHIBITORS GANETESPIB AND NVP-AUY922
    Publication number: 20160324863
    Abstract: Methods of treating certain cancers with ganetespib or NVP-AUY922 are disclosed. Also provided are methods of treating cancer wherein the cancer has an FGFR3 mutation and/or a low level expression of UGT1A, and/or a low level expression of UGT1A9 and/or UGT1A10. Also provided are methods of treating cancer with a mutation in FGFR3 and/or a low level expression of UGT1A, and/or a low level expression of UGT1A9 and/or UGTIA10, with ganetespib or NVP-AUY922, in combination with an FGFR3 inhibitor such as BGJ398 and AZD4547.
    Type: Application
    Filed: January 16, 2015
    Publication date: November 10, 2016
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Jaime Acquaviva, David Proia
  • SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS
    Publication number: 20160324864
    Abstract: Provided are pyridopyrazine compounds of formula (I), pharmaceutical compositions thereof and methods of use therefore, wherein R1, R2, R3, R4 and m are as defined in the specification.
    Type: Application
    Filed: July 15, 2016
    Publication date: November 10, 2016
    Inventors: Wei-Guo SU, Wei DENG, Jianguo JI
  • TRICYCLIC PYRAZOLE SULPHONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME
    Publication number: 20160324865
    Abstract: The invention provides tricyclic sulfonamide compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.
    Type: Application
    Filed: December 14, 2015
    Publication date: November 10, 2016
    Inventors: Susan M. Cramp, Hazel J. Dyke, Thomas D. Pallin, Robert Zahler
  • INHIBITORS OF THE PLASMODIAL SURFACE ANION CHANNEL AS ANTIMALARIALS
    Publication number: 20160324866
    Abstract: Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein R1 to R7 are as described herein.
    Type: Application
    Filed: July 18, 2016
    Publication date: November 10, 2016
    Inventors: Sanjay A. Desai, Ajay D. Pillai
  • METHODS OF TREATING SKIN DISORDERS
    Publication number: 20160324867
    Abstract: A method of treating a skin disorder (e.g., an inflammatory or neoplastic skin disorder) in a subject in need thereof is carried out by administering (e.g., topically administering) the subject an active agent in a treatment effective amount. The active agent may be a compound of Formula I: wherein: each R is independently selected substituted or unsubstituted aryl, heteroaryl, cycloalkyl, or heterocycloalkyl; each A is an independently selected hydrogen, an electron-withdrawing group, or electron donating group; M is a metal; and Z? is a counterion; or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 21, 2015
    Publication date: November 10, 2016
    Inventors: James D. Crapo, Kimberly C. Stone
  • METHODS OF TREATING PRURITUS
    Publication number: 20160324868
    Abstract: A method of treating pruritus (itching) in a subject in need thereof is carried out by administering the subject an active agent in a treatment effective amount, wherein the active agent is a superoxide dismuate (SOD) mimetic. The SOD mimetic can be a complex of a metal (e.g., manganese) and an organic ligand, with suitable organic ligands including porphyrins, polyamines, salens, nitroxides, and fullerenes. Compositions for carrying out such methods are also described.
    Type: Application
    Filed: January 21, 2015
    Publication date: November 10, 2016
    Inventors: Ru-Rong Ji, Tong Liu, Ines Batinic-Haberle, David S. Warner, Kimberly C. Stone, James D. Crapo
  • Methods of Cosmetically Treating Skin Conditions With A Cosmetic Personal Cleansing Composition
    Publication number: 20160324869
    Abstract: A method of treating a skin condition including applying a rinse-off multi-phase cleansing composition including a cleansing phase including an anionic surfactant and zinc pyrithione and a benefit phase including a benefit agent.
    Type: Application
    Filed: May 6, 2016
    Publication date: November 10, 2016
    Inventors: Karl Shiqing WEI, Jason Edward COOK, Kevin John MILLS
  • TREATMENT OF MIGRAINES
    Publication number: 20160324870
    Abstract: Provided herein are prostaglandin F2alpha analog compositions and methods for treating migraines by topical administration. The method involves administering topically to a subject in need thereof a composition including a prostaglandin F2apha analog or pharmaceutically acceptable salt thereof, in an amount effective to treat migraine. The treatment may be administered prophylactically or therapeutically. Topical administration is to the epidermis, conjunctival surface or other mucous membranes, typically to a nail, the skin, the hair, the surface of the eye or the inner surface of the eyelid, and the like. The prostaglandin F2a analog can be latanoprost, isopropyl unoprostone, bimatoprost, travoprost, or tafluprost; or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 9, 2015
    Publication date: November 10, 2016
    Applicant: Manistee Partners LLC
    Inventors: Robert L. Bratzler, Martin Wand, Frederick Ryckman, Bradford J. Shingleton
  • Hypotensive lipid-containing biodegradable intraocular implants and related methods
    Publication number: 20160324871
    Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Application
    Filed: July 15, 2016
    Publication date: November 10, 2016
    Inventor: Patrick M. Hughes
  • IMPREGNATED DRESSINGS FOR TREATING DERMATOLOGICAL DISORDERS
    Publication number: 20160324872
    Abstract: This document provides methods and materials for treating dermatologic disorders. For example, methods and materials for using dressings (e.g., wet dressings) to treat dermatologic conditions such as dermatitis are provided.
    Type: Application
    Filed: January 8, 2015
    Publication date: November 10, 2016
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Alison J. Bruce, Charles J. Bruce, Benjamin J. Barrick
  • Enzymatic Process for Obtaining 17 Alpha-Monoesters of Cortexolone and/or its 9,11-Dehydroderivatives
    Publication number: 20160324873
    Abstract: The present invention refers to a new enzymatic process for obtaining 17?-monoesters of cortexolone and/or its 9,11-dehydroderivatives starting from the corresponding 17?,21-diesters which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to new crystalline forms of cortexolone-17?-propionate and 9,11-dehydro-cortexolone 17?-butanoate.
    Type: Application
    Filed: July 15, 2016
    Publication date: November 10, 2016
    Inventors: Mauro AJANI, Luigi MORO
  • RETINOID X RECEPTOR-GAMMA AGONISTS AND RETINOID X RECEPTOR-ALPHA ANTAGONISTS FOR TREATMENT OF CANCER
    Publication number: 20160324874
    Abstract: The invention is directed to the use of Retinoid X Receptor-gamma (RXR-gamma) agonists and Retinoid X Receptor-alpha (RXR-alpha) antagonists in treatment of cancer.
    Type: Application
    Filed: October 24, 2014
    Publication date: November 10, 2016
    Applicant: St. Jude Children's Research Hospital, Inc.
    Inventors: Wai-Hang LEUNG, Wing LEUNG
  • CUTANEOUS COMPOSITION COMPRISING VITAMIN D ANALOGUE AND A MIXTURE OF SOLVENT AND SURFACTANTS
    Publication number: 20160324875
    Abstract: A pharmaceutical composition comprising a vitamin D derivative or analogue as the active ingredient dissolved in a three-component surfactant-solvent mixture is useful in the treatment of dermal disorders or conditions.
    Type: Application
    Filed: July 19, 2016
    Publication date: November 10, 2016
    Applicant: LEO PHARMA A/S
    Inventor: Karsten PETERSSON
  • VITAMIN D AND ANTIBACTERIAL USES OF COMPOSITIONS THEREOF
    Publication number: 20160324876
    Abstract: Uses of a vitamin D compound in the preparation of drugs for preventing or treating cystitis, urethritis and/or urinary tract infection, as well as a pharmaceutical composition, a pharmaceutical preparation and a kit that comprise the vitamin D compound, the vitamin D compound comprising a vitamin D2, a vitamin D3, an active form of the vitamin D3 or a similar substance, and the active form of the vitamin D3 being 25-hydroxyvitamin D3 or 1,25-dihydroxyvitamin D3.
    Type: Application
    Filed: December 25, 2014
    Publication date: November 10, 2016
    Inventor: Mingdong Zhou
  • COMBINATION OF VITAMIN D AND 25-HYDROXYVITAMIN D 3
    Publication number: 20160324877
    Abstract: We disclose compositions comprising Vitamin D (cholecalciferol and /or ergocalciferol) and 25-OH D3 (calcifediol), and use of those compositions to affect at least concentration, bioavailability, metabolism, or efficacy of vitamin D in a human. Forms and dosages of the composition, as well as processes for manufacturing a spray-dried formulation, are also disclosed.
    Type: Application
    Filed: July 20, 2016
    Publication date: November 10, 2016
    Inventors: Neil Robert BUCK, Wouter CLAERHOUT, Bruno H. LEUENBERGER, Elisabeth STOECKLIN, Kai URBAN, Swen WOLFRAM
  • PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASES
    Publication number: 20160324878
    Abstract: Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of BTK, mTOR kinase, and Bcl-2 or their signaling pathways, and immunomodulatory drugs. Also described are pharmaceutical compositions and kits comprising these inhibitors.
    Type: Application
    Filed: June 15, 2016
    Publication date: November 10, 2016
    Applicant: Zhejiang DTRM Biopharma Co. Ltd.
    Inventor: Wei He
  • SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND
    Publication number: 20160324879
    Abstract: Crystalline forms, including salts and polymorphs, of a compound useful in the treatment of tetracycline compound-responsive states are provided herein. The crystalline compounds are useful for the treatment or prevention of conditions and disorders such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds in general.
    Type: Application
    Filed: December 8, 2015
    Publication date: November 10, 2016
    Inventors: Raymond Cvetovich, Tadeusz Warchol
  • 4-DEDIMETHYLAMINO TETRACYCLINE COMPOUNDS
    Publication number: 20160324880
    Abstract: The present invention pertains, at least in part, to novel substituted 4-dedimethylamino tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
    Type: Application
    Filed: December 8, 2015
    Publication date: November 10, 2016
    Inventors: Mark L. Nelson, Kwasi Ohemeng
  • Neurokinin-1 Receptor Antagonists For Use In A Method Of Prevention Of Cancer
    Publication number: 20160324881
    Abstract: Subject matter of the present invention is a neurokinin-1 receptor antagonist for use in a method of prevention of cancer. Particularly, subject matter of the present invention is a neurokinin-1 receptor antagonist according to the compounds of Formula (I) or a tautomer thereof or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable salt of a tautomer thereof for use in a method of preventing cancer. In a very specific embodiment the non-peptide antagonist fosaprepitant sir aprepitant is said neurokinin-1 receptor antagonist. In another specific embodiment, subject matter of the present invention is a neurokinin-1 receptor antagonist for use in a method of preventing cancer as monotherapeutic agent.
    Type: Application
    Filed: December 29, 2014
    Publication date: November 10, 2016
    Applicant: ONCOPREVENT GMBH
    Inventor: Andreas BERGMANN
  • Therapeutic Compositions Comprising Imidazole and Imidazolium Compounds
    Publication number: 20160324882
    Abstract: Therapeutic compositions comprising substituted imidazole or imidazolium compounds may be used for a number of medical purposes, such as treatment of undesirable conditions or diseases, including disease or conditions related to bone, cancer, and/or pain.
    Type: Application
    Filed: July 15, 2016
    Publication date: November 10, 2016
    Inventor: Herriot Tabuteau
  • CATIONIC POLYMERS AS CO-DRUGS FOR CHEMOTHERAPEUTIC AGENTS
    Publication number: 20160324883
    Abstract: A method for treating a biological cell is disclosed. The method administers a mixture of a chemotherapeutic drug and a co-drug that facilitates delivery of the chemotherapeutic drug to the nucleus of the cell. Examples of co-drugs include cationic polymers, cationic lipids and cationic proteins. Cationic polymers include a polyethyleneimine (PEI), polylysine, a polybetaaminoester (PBAE), an ?-polylysine (EPL) including ?-poly-L-lysine (e-PLL), a polyarginine peptide, chitosan, a polyamidoamine dendrimer (PAMAM). Cationic lipids include 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP). Cationic proteins include protamine.
    Type: Application
    Filed: May 4, 2016
    Publication date: November 10, 2016
    Inventors: Debra Auguste, Daxing Liu
  • TREATMENT OF DIABETES WITH PENTACYCLIC TRITERPENOID SAPONIN COMPOUNDS FROM SZECHUAN MELANDIUM ROOT
    Publication number: 20160324884
    Abstract: The method for treating diabetes in an individual includes the step of administering a therapeutically effective amount of a pharmaceutically acceptable pentacyclic triterpenoid saponin compound to the individual suitable to provide therapeutic levels of insulin to the individual. The compound can be administered by injection, transdermal contact, or nasal spray. The method includes mixing the compound with an additive into an ingestible so that the therapeutic effective amount passes through the gastric acid of the stomach to the bloodstream.
    Type: Application
    Filed: July 18, 2016
    Publication date: November 10, 2016
    Inventors: Xueyong WANG, Baosheng ZHAO
  • COMPOSITION CONTAINING MODIFIED DERIVATIVES OF A CYTIDINE ANTIMETABOLITE FOR THE TREATMENT OF SUSCEPTIBLE DISEASE
    Publication number: 20160324885
    Abstract: The present invention relates to homo-oligomeric derivatives of a cytidine antimetabolite and its use for the treatment of susceptible diseases. The cytidine antimetabolite is preferably a compound made of 2-20 units of dFdC linked with 5?-3? phosphate bonds.
    Type: Application
    Filed: July 10, 2013
    Publication date: November 10, 2016
    Applicant: Asteriapharma GmbH
    Inventor: Victoria Juarez Guerra
  • CHITOSAN DERIVATIVES FOR INACTIVATION OF ENDOTOXINS AND SURFACE PROTECTION OF NANOPARTICLES
    Publication number: 20160324886
    Abstract: The present disclosure provides a polymer comprising a derivative of chitosan, wherein the derivative is zwitterionic, as well as methods of using the polymer. In addition, the present disclosure provides a nanoparticle structure comprising a derivative of chitosan and a dendrimer, as well as methods of utilizing the nanoparticle structure.
    Type: Application
    Filed: July 18, 2016
    Publication date: November 10, 2016
    Applicant: Purdue Research Foundation
    Inventors: Yoon YEO, Gaurav BAJAJ, Peisheng XU, Karen LIU, Eun Jung CHO
  • BINDING OF GALECTIN-3 BY LOW MOLECULAR WEIGHT PECTIN
    Publication number: 20160324887
    Abstract: Administration of low molecular weight (10,000-20,000 Daltons, or lower) pectins, particularly modified citrus pectins (MCP), like PectaSol-C reduces galectins-3 levels in vivo. Reduction of galectin-3 levels by MCP inhibits inflammation, inhibits fibrosis formation in organs and tissues, and inhibits cancer formation, progression, transformation and metastases. The reduction in circulating, serum and cellular galectin-3, inherently resulting from the administration of MCP, provides benefit over a spectrum of biological conditions, as evidenced by in vivo trials.
    Type: Application
    Filed: July 20, 2016
    Publication date: November 10, 2016
    Applicant: ECONUGENICS, INC.
    Inventor: Isaac ELIAZ
  • METHOD FOR TREATING INTERVERTEBRAL DISC DEGENERATION
    Publication number: 20160324888
    Abstract: An injectable carboxymethylcellulose (CMC) and methylcellulose (MC) hydrogel derived from the plant-based polysaccharide, cellulose, is provided which gels in situ and repairs the intervertebral disc in the spinal column or other cartilaginous tissues. One specific application is for replacement of the nucleus pulposus (NP), the central gelatinous region of the intervertebral disc, following injury or degeneration.
    Type: Application
    Filed: May 6, 2016
    Publication date: November 10, 2016
    Inventors: Steven B. Nicoll, Devika Varma
  • HIGHLY STABLE ELECTROLYTIC WATER WITH REDUCED NMR HALF LINE WIDTH
    Publication number: 20160324889
    Abstract: Electrolytic acid or alkaline water having a NMR half line width using 170 of from about 45 to less than 51 Hz, and an oxide reduction potential of from ?1000 to +200 mV, or from +600 to +1300 mV, topical compositions that contain such water, uses for such water to hydrate skin, deliver drugs and treat various skin and mucosal conditions, and methods and apparatus for manufacturing the water.
    Type: Application
    Filed: July 19, 2016
    Publication date: November 10, 2016
    Applicant: APR NANOTECHNOLOGIES s.a.
    Inventors: Yongge CHEN, Roberto DE NONI
  • Method and Device for Preventing Microbial Resistance
    Publication number: 20160324890
    Abstract: A method to treat acute sinusitis as an alternative to prescribing an antibiotic or recommending over-the-counter medications by (1) providing a non-antibiotic treatment package containing a pharmacy-dispensed decongestant and an over-the-counter therapeutic agent for acute sinusitis that includes a topical nasal moisturizing means, and further selecting pseudoephedrine that is pharmacy-dispensed wherein the non-antibiotic treatment package is a behind-the-counter treatment package, (2) advising a patient to procure the treatment package to treat acute sinusitis as an alternative to prescribing an antibiotic or recommending over-the-counter procurement of treatment, and (3) pharmacy-dispensing the treatment package to a patient.
    Type: Application
    Filed: September 15, 2015
    Publication date: November 10, 2016
    Inventors: Robert E. Weinstein, Allan M. Weinstein
  • NANOCLUSTERED WATER HAVING IMPROVED MEDICAL UTILITY
    Publication number: 20160324891
    Abstract: The present invention relates to methods of treating or preventing an infection or infectious disease in a mammal, or sanitizing mammalian tissue, or treating or preventing psoriasis in a mammal, comprising topically administering to said mammal an electrolytic acid water comprising free chlorine, wherein: a) from 90% to 99.9% of said free chlorine is present in the form of hypochlorous acid; b) said water has a pH of from 0.5 to 5.0; and c) said water has oxidation reduction potential (ORP) of greater than 1100 mV. The present invention also relates to methods of healing, repair or regeneration of a tissue in a mammal comprising topically administering to said tissue said electrolytic acid water.
    Type: Application
    Filed: July 22, 2016
    Publication date: November 10, 2016
    Applicant: APR NANOTECHNOLOGIES s.a.
    Inventors: Yongge CHEN, Roberto DE NONI, Giorgio REINER
  • BACTERICIDAL COMPOSITION FOR BACTERIAL SKIN DISEASE
    Publication number: 20160324892
    Abstract: [Problem] To provide a bactericidal composition for bacterial skin disease against which it is difficult for bacteria that cause bacterial skin disease to acquire drug resistance. [Solution] A bactericidal composition for bacterial skin disease that is characterized by including silver iodide in the form of nanoparticles having a particle size of 1-100 nm, inclusive, iodide ions, a water-soluble polymer, and an organic acid having a carboxyl group, and/or a salt of said acid, wherein the molar ratio of silver to iodide ions in the silver iodide is 1:1-1:1000.
    Type: Application
    Filed: February 6, 2015
    Publication date: November 10, 2016
    Applicant: NBC MESHTEC INC.
    Inventors: Yoko FUKUI, Eri MAZUYAMA, Yoshie FUJIMORI, Tomokazu NAGAO, Tsuruo NAKAYAMA
  • CALCIUM POLYPHOSPHATE SALTS, METHODS OF MAKING AND USE IN BEVERAGE COMPOSITIONS
    Publication number: 20160324893
    Abstract: An equilibrium solution, such as a beverage product, containing a calcium salt of a sequestrant (such as calcium hexametaphosphate), coordinated compound of a calcium sequestrant and a sequestrant allows the delivery of bio-available calcium while maintaining the preservative qualities of the sequestrant (such as sodium hexametaphosphate). In one embodiment, the reaction of a salt such as calcium hydroxide and a sequestrant such as sodium potassium hexametaphosphate (sodium potassium polyphosphate) yields such an equilibrium solution in a beverage matrix. Calcium hexametaphosphate having a relatively short phosphate chain is disclosed, as well as the method of making that material, and beverage compositions containing the material together with a sequestrant preservative, such as SHMP.
    Type: Application
    Filed: March 10, 2016
    Publication date: November 10, 2016
    Inventors: Gregory ARCUINO, Robert J. SARAMA
  • GALECTIN-3 PLASMAPHERESIS THERAPY
    Publication number: 20160324894
    Abstract: The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer.
    Type: Application
    Filed: July 20, 2016
    Publication date: November 10, 2016
    Applicant: ELIAZ THERAPEUTICS, INC.
    Inventor: ISAAC ELIAZ
  • MODIFIED NATURAL KILLER CELLS, COMPOSITIONS AND USES THEREOF
    Publication number: 20160324895
    Abstract: Modified natural killer cells, pharmaceutical compositions comprising the modified natural killer cells and at least one pharmaceutically acceptable carrier or excipient, uses of the modified natural killer cells, and methods for identifying depleted natural killer cells and culturing the modified natural killer cells are provided.
    Type: Application
    Filed: December 23, 2014
    Publication date: November 10, 2016
    Inventor: Jan Mou LEE
  • LUTERIAL AND METHOD FOR ISOLATING AND CULTURING THE SAME
    Publication number: 20160324896
    Abstract: The present invention relates to blood-derived luterial and a method for isolating and culturing the same. The luterial according to the present invention is a cell or cell-like structure having the following characteristics: (1) it is present in body fluids, including blood, sperm, intestinal juices, saliva, and cellular fluids; (2) it shows a positive staining with Janus green B, Acridine Orange and Rhodamine 123 in an immunofluorescence test; (3) in an optimal environment (pH 7.2-7.
    Type: Application
    Filed: May 9, 2014
    Publication date: November 10, 2016
    Inventors: Won Cheol CHOI, Young Ah KWON, Suk Hoon Choi, Chang Hoon Choi
  • PLATELET DECOYS AND USE THEREOF
    Publication number: 20160324897
    Abstract: The invention provides platelet decoys and mimics that can bind to platelet receptor substrate but do not undergo platelet activation. The invention also provides methods of using the platelet decoys for treating, preventing or inhibiting a disease or disorder in subject when platelet activation, aggregation and/or adhesion contributes to the pathology or symptomology of the disease.
    Type: Application
    Filed: January 16, 2015
    Publication date: November 10, 2016
    Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Donald E. INGBER, Anne-Laure PAPA
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
    Publication number: 20160324898
    Abstract: Compositions of mesenchymal stem cells and mesenchymal stem cell factors are provided. Methods of using the inventive compositions in the treatment of Alzheimer's disease are contemplated.
    Type: Application
    Filed: January 15, 2016
    Publication date: November 10, 2016
    Applicant: Stemedica International, SA
    Inventors: Tristan Bolmont, Nikolai Tankovich
  • MULTIPOTENT AND IMMUNOCOMPATIBLE STEM CELL CONCENTRATE
    Publication number: 20160324899
    Abstract: The present invention generally relates to a stem cell concentrate isolated from a mammalian vascularized adipose tissue, biopharmaceuticals containing such concentrate and use thereof in therapies for treating diseases in mammals.
    Type: Application
    Filed: December 22, 2014
    Publication date: November 10, 2016
    Inventors: Alexandre KERKIS, Cristiane Valverde WENCESLAU, Michele Andrade De BARROS, João Flávio Panattoni MARTINS
  • LIVER STROMAL CELLS FOR PREVENTION AND TREATMENT OF IMMUNE RESPONSES IN TRANSPLANTATION
    Publication number: 20160324900
    Abstract: The present invention encompasses methods and compositions for reducing an immune response to a transplant in a recipient by treating said recipient with an amount of liver stromal cells effective to reduce or inhibit host rejection of the transplant. Also disclosed is a method of inducing a reduced immune response against a host by foreign tissue, i.e., graft versus host disease, by treatment with liver stromal cells.
    Type: Application
    Filed: July 19, 2016
    Publication date: November 10, 2016
    Inventor: Kevin R. McIntosh
  • Stem Cells Derived from Basal Portion of Chorionic Trophoblast Layer and Cell Therapy Comprising Same
    Publication number: 20160324901
    Abstract: The present disclosure relates to stem cells derived from the basal portion of the chorionic trophoblast layer (bCT), which is a part of the issues of the placenta, and cell therapy comprising same. Stem cells derived from the basal portion of the chorionic trophoblast layer according to the present invention exhibit uniform growth characteristic, and superb proliferation and differentiation characteristic as compared with the conventional stem cells derived from the full placenta or other tissues, and exhibit excellent tissue regeneration effect in an animal model, thus can be effectively used in cell therapy.
    Type: Application
    Filed: January 8, 2015
    Publication date: November 10, 2016
    Inventors: Chul Won HA, Jin A. KIM
  • UMBILICAL CORD AMNIOTIC MEMBRANE PRODUCTS
    Publication number: 20160324902
    Abstract: Disclosed herein, in certain instances, are tissue grafts derived from UCAM. Further disclosed herein, in certain instances, are use for tissue grafts derived from UCAM.
    Type: Application
    Filed: July 20, 2016
    Publication date: November 10, 2016
    Inventors: Scheffer TSENG, Ek Kia TAN, Amy TSENG
  • LISTERIA-BASED ADJUVANTS
    Publication number: 20160324903
    Abstract: This invention provides methods and compositions for using Listeria monocytogenes as an adjuvant for enhancing immune responses in a subject.
    Type: Application
    Filed: July 27, 2016
    Publication date: November 10, 2016
    Applicants: ADVAXIS, INC., THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventors: John ROTHMAN, Anu WALLECHA, Reshma SINGH, Donald A. HARN, JR., Yvonne PATERSON
  • SUPPLEMENT FOR IMPROVING IMMUNOTOLERANCE, INTESTINAL ENVIRONMENT AND INTESTINAL TRACT BARRIER
    Publication number: 20160324904
    Abstract: A supplement for improving immunotolerance, intestinal environment and intestinal tract barrier for the purpose of improving intestinal vulnerability, food intolerance or allergy, systemic allergy, autoimmune diseases and systemic inflammatory diseases by immune reactions which is obtained by mixing an ingredient (A) comprising at least one of a probiotic that is any one of lactic acid bacteria, Lactobacillus bifidus, saccharified bacteria, natto bacteria and yeast fungus, or a mixture thereof, a biogenic that is a bacteria-producing substance such as lactic acid bacteria, and a prebiotic is indigestible food ingredients such as oligosaccharide, dietary fiber, substance stimulating production of Lactobacillus bifidus, and others or a mixture thereof and an ingredient (B) comprising at least one of L-glutamine, zinc, vitamin A and vitamin D.
    Type: Application
    Filed: May 5, 2015
    Publication date: November 10, 2016
    Inventor: Ryozo SAITO
  • RECOMBINANT LACTOBACILLUS WITH DECREASED LIPOTEICHOIC ACID TO REDUCE INFLAMMATORY RESPONSES
    Publication number: 20160324905
    Abstract: Methods and compositions for treating or preventing inflammatory disorders are provided. The compositions of the invention comprise a recombinant bacterium genetically modified to decrease the display of lipoteichoic acid on the cell surface. Methods of the invention comprise administering to a subject a recombinant bacterium modified to decrease the display of lipoteichoic acid on the cell surface. Administration of the recombinant bacterium promotes a desired therapeutic response. The recombinant bacterium may be administered in a single dose or series of doses. Methods of the invention find use in treating or preventing a variety of inflammatory disorders including, for example, treating or preventing inflammatory bowel disease, colitis, or Crohn's disease.
    Type: Application
    Filed: April 13, 2016
    Publication date: November 10, 2016
    Applicants: North Carolina State University, Northwestern University
    Inventors: Todd R. Klaenhammer, Erika Pfeiler, Mansour Mohamadzadeh
  • PHARMACEUTICAL COMPOSITION INCLUDING DEAD CELLS OF LACTOBACILLUS ACIDOPHILUS LB TO TREAT OR PREVENT ALLERGIC DISEASE
    Publication number: 20160324906
    Abstract: Disclosed is a pharmaceutical composition including dead cells of Lactobacillus acidophilus LB strain as an active ingredient for treating or preventing an allergic disease, and may be used to treat and prevent IgE-mediated allergic diseases and non-IgE-mediated allergic diseases such as atopic dermatitis, allergic rhinitis, allergic conjunctivitis, urticaria, and pollinosis by reducing the total content of IgE in the blood.
    Type: Application
    Filed: July 22, 2016
    Publication date: November 10, 2016
    Inventor: Dae Hyun KIM
  • POMEGRANATE SKIN EXTRACT FOR TREATING FATTY LIVER
    Publication number: 20160324907
    Abstract: Use of a pomegranate skin extract for use in the treatment of metabolic syndrome, more particularly, fatty liver disease. More particularly, the pomegranate skin extract is used in inhibiting body weight gain in the prevention and/or the treatment of fatty liver disease in mammals.
    Type: Application
    Filed: January 9, 2014
    Publication date: November 10, 2016
    Applicant: NESTEC S.A.
    Inventors: Ignatius Szeto, Peifang Zhang, Weiguo Zhang, Junkuan Wang, Cheih Jason Chou
  • Oil Exraction From Processed Hemp
    Publication number: 20160324908
    Abstract: Oil is extracted from processed hemp which is better suited for transportation than whole hemp stalks particularly when oil extraction and initial processing of the hemp from the whole hemp stalks is performed at separate facilities. For example, the processed hemp may be characterized in that it was pelletized as part of its processing from the whole hemp stalks. Used processed hemp lacking/deprived of oil that is generated from the step of extracting the cannabinoid oil may be reused in a vendible product, for example where the lack of oil does not alter performance of the hemp in use of that vendible product.
    Type: Application
    Filed: May 5, 2016
    Publication date: November 10, 2016
    Inventor: Lyall D. Bates
  • HYDROGENATION OF CANNABIS OIL
    Publication number: 20160324909
    Abstract: The present invention relates to the extraction and hydrogenation of essential oil of a cannabis plant. The invention includes hydrogenated cannabis compounds and compositions, as well as methods of preparation and therapeutic uses for regressing tumors in a cancer patient. The extract can include 9-tetrahydrocannabinoic acid and 9-cannabidiolic acid, and the hydrogenated cannabis oil can include hydrogenated 9-tetrahydrocannabinoic acid, hydrogenated 9-cannabidioc acid and, mixtures and blends thereof.
    Type: Application
    Filed: May 9, 2016
    Publication date: November 10, 2016
    Inventor: MARK ANDREW SCIALDONE